Background: In line with the paradigm to minimize surgical morbidity in patients with primary breast cancer, there is increasing evidence for the safety of a repeat breast-conserving treatment (BCT) of an ipsilateral breast tumour recurrence (IBTR) in selected patients. The conditions for the feasibility of a repeat BCT vary widely in literature. In clinical practice, many physicians have ongoing concerns about the oncological safety and possible toxicity of repeat BCT.
Aim: To investigate the attitude of Dutch breast surgeons and radiation oncologists towards repeat BCT and to report on their experiences with, objections against and perceived requirements to consider a repeat BCT in case of IBTR.
Patients And Methods: An online survey consisting of a maximum of 26 open and multiple-choice questions about repeat BCT for IBTR was distributed amongst Dutch breast surgeons and radiation oncologists.
Results: Forty-nine surgeons representing 49% of Dutch hospitals and 20 radiation oncologists representing 70% of Dutch radiation oncology centres responded. A repeat BCT was considered feasible in selected cases by 28.7% of breast surgeons and 55% of radiation oncologists. The most important factors to consider a repeat BCT for both groups were the patient's preference to preserve the breast and surgical feasibility of a second lumpectomy. Arguments against a repeat BCT were based on the perceived unacceptable toxicity and cosmesis of a second course of radiotherapy. The technique of preference for re-irradiation would be partial breast irradiation (PBI) according to all radiation oncologists. Differentiating between new primary tumours (NPT) and true recurrences (TR) was reported to be done by 57.1% of breast surgeons and 60% of radiation oncologists. The most important reason to differentiate between NPT and TR was to establish prognosis and to consider whether a repeat BCT would be feasible.
Conclusion: An increasing number of Dutch breast cancer specialists is considering a repeat BCT feasible in selected cases, at the patient's preference and with partial breast re-irradiation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189996 | PMC |
| http://dx.doi.org/10.1007/s10549-021-06154-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of F-FDG PET/CT in detecting synchronous regional and distant metastatic disease in patients with an in-breast tumour recurrence.
Eur J Surg Oncol
December 2024
Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands.
Background: In line with the trend towards minimally invasive, patient-tailored treatment, a selected group of patients with an in-breast tumour recurrence (IBTR) is treated by repeat breast-conserving treatment (BCT). To select eligible patients for repeat BCT, a reliable pre-operative work-up is essential. This study reports on the role of F-FDG PET/CT in detecting synchronous regional and distant metastases in patients with IBTR.
View Article and Find Full Text PDFA toxicology study of complementation and pulmonary macrophage transplantation therapy of hereditary PAP in mice.
Mol Ther Methods Clin Dev
June 2024
Translational Pulmonary Science Center, Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, OH, USA.
Article Synopsis
- Pulmonary macrophage transplantation (PMT) is a developing therapy aimed at treating hereditary pulmonary alveolar proteinosis (hPAP) by using gene-corrected macrophages (mGM-RαMϕs).
- A toxicology study on mice showed that PMT was safe and well tolerated, with no significant adverse effects, including no uncontrolled cell growth or lung problems.
- Results indicated that PMT effectively reduced lung disease severity in mice while establishing a substantial safety margin.
Novel and Engineered Type II CRISPR Systems from Uncultivated Microbes with Broad Genome Editing Capability.
CRISPR J
June 2023
Metagenomi, Inc., Discovery, Emeryville, California, USA.
Type II Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 nucleases have been extensively used in biotechnology and therapeutics. However, many applications are not possible owing to the size, targetability, and potential off-target effects associated with currently known systems. In this study, we identified thousands of CRISPR type II effectors by mining an extensive, genome-resolved metagenomics database encompassing hundreds of thousands of microbial genomes.
View Article and Find Full Text PDFCompact Cas9d and HEARO enzymes for genome editing discovered from uncultivated microbes.
Nat Commun
December 2022
Metagenomi Inc. 1545 Park Ave, Emeryville, CA, 94608, USA.
Programmable, RNA-guided nucleases are diverse enzymes that have been repurposed for biotechnological applications. However, to further expand the therapeutic application of these tools there is a need for targetable systems that are small enough to be delivered efficiently. Here, we mined an extensive genome-resolved metagenomics database and identified families of uncharacterized RNA-guided, compact nucleases (between 450 and 1,050 aa).
View Article and Find Full Text PDFImpact of Early Weightbearing After Ankle Arthroscopy and Bone Marrow Stimulation for Osteochondral Lesions of the Talus.
Orthop J Sports Med
September 2021
Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Background: Osteochondral lesion of the talus (OLT) may be caused by osteochondritis dissecans, osteochondral fractures, avascular necrosis, or focal arthritic changes. For certain focal cartilage defects, bone marrow stimulation (BMS) has been a widely used technique to restore a fibrocartilage substitute overlying the defect. There are various postoperative weightbearing protocols for this procedure, with no single gold standard method.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!